R&D Collaboration and EU projects
Vectiopep participates in several international and national research programmes and projects.
Enterprise Estonia Project 2021-2027.1.01.25-1008.
Protection of Intellectual Property of Vectiopep OÜ.
The project helps us expand the global protection of the company’s intellectual property, build trust, and ensure a competitive advantage.
As a result of the project: Vectiopep OÜ has successfully entered the national registration phases with patent application WO2024074553A1, securing protection for its mRNA delivery technology in Australia, China, Japan, and Canada.
Project funding: 7 500 €
Project duration: 07.04.2025 – 01.10.2025
Business development support for deep-tech startups.
Enterprise Estonia Project RE.5.04.25-0828
Vectiopep OÜ is developing mRNA-based cancer therapy that helps the immune system fight cancer. The company plans to conduct its first clinical trials within the next 3.5 years. To achieve this, we are seeking international investors, building relationships with pharmaceutical companies, preparing a clear regulatory roadmap, and testing the market suitability of our technology
As a result of this project, the goal is to attract international investors who would invest at least 6 million euros into the company for conducting the first phase of the clinical trial
Project funding: 47 499.75 €
Project duration: 14.04.2025 – 13.04.2026
The project is funded from the state budget through research and development funding instruments.